Less Haste, More Speed? Do European Accelerated Authorisations Translate Into Early Reimbursement And Patient Access?

October 4, 2018 Danielle Twigg

Medicines of a major interest for public health can qualify for an Accelerated Assessment (AA) by the European Medicines Agency (EMA), reducing the centralised assessment timeframe from 210 days to 150 days. In 2016, the AA procedural framework was optimised and the PRIority MEdicines (PRIME) scheme was introduced to facilitate greater utilisation of the AA process. However, to reach patients, medicines must also be publically reimbursed. This research aims to assess the reimbursement outcomes of major public payer bodies for all medicines approved under AAs.

Authors: Macaulay R1, Wang GD1, Magimaidas A2
1PAREXEL International, London, United Kingdom, 2PAREXEL International, Horsham, PA, USA

To find out more about this poster you can register to download it here after the ISPOR event.

Previous Article
Payer Archetyping – Expanding Horizons
Payer Archetyping – Expanding Horizons

Next Article
A Comparison Of P&R Requirements For Orphan Drugs In 25 Markets
A Comparison Of P&R Requirements For Orphan Drugs In 25 Markets